135 related articles for article (PubMed ID: 15089772)
1. Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
Piccaluga PP; Malagola M; Rondoni M; Amabile M; Paolini S; Soverini S; Gaitani S; Visani G; Baccarani M; Martinelli G
Eur J Haematol; 2004 Apr; 72(4):302-3. PubMed ID: 15089772
[No Abstract] [Full Text] [Related]
2. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
[TBL] [Abstract][Full Text] [Related]
3. Imatinib for relapsed BCR/ABL positive leukemias.
Ottmann OG; Wassmann B; Hoelzer D
Ann Hematol; 2002; 81 Suppl 2():S36-7. PubMed ID: 12611069
[No Abstract] [Full Text] [Related]
4. Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella AM
Expert Rev Anticancer Ther; 2007 Mar; 7(3):249-51. PubMed ID: 17338645
[No Abstract] [Full Text] [Related]
5. Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias.
Gupta V; Kamel-Reid S; Minden MD; Lipton JH; Brandwein J; Messner HA
Hematology; 2003 Jun; 8(3):139-43. PubMed ID: 12745646
[TBL] [Abstract][Full Text] [Related]
6. Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
Li Y; Qiu L; Zou D; Zhao Y; Mi Y; Wang J
Ann Hematol; 2009 Nov; 88(11):1069-77. PubMed ID: 19277658
[TBL] [Abstract][Full Text] [Related]
7. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
[TBL] [Abstract][Full Text] [Related]
8. Combination of imatinib and established antileukemic treatment modalities for otherwise refractory BCR-ABL positive lymphoblastic leukemia.
Fruehauf S; Topaly J; Buss EC; Schad M; Goerner M; Zeller WJ; Ho AD
Haematologica; 2002 Dec; 87(12):ECR38. PubMed ID: 12495909
[No Abstract] [Full Text] [Related]
9. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
Grammatico S; Elia L; Peluso AL; Pedace L; Matarazzo M; Vitale A; Rago A; Pane F; Foà R; Cimino G
Leuk Res; 2009 Jul; 33(7):e73-4. PubMed ID: 19108887
[No Abstract] [Full Text] [Related]
10. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
11. Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.
Brandwein JM; Gupta V; Wells RA; Schuh AC; Schimmer AD; Lipton JH; Messner HA; Yi QL; Chun K; Kamel-Reid S; Minden MD
Leuk Res; 2005 Dec; 29(12):1381-6. PubMed ID: 15927253
[TBL] [Abstract][Full Text] [Related]
12. The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients.
Piccaluga PP; Malagola M; Amabile M; Rondoni M; Paolini S; Pane F; Russo D; Visani G; Baccarani M; Martinelli G
Haematologica; 2004 Oct; 89(10):1269-71. PubMed ID: 15477218
[TBL] [Abstract][Full Text] [Related]
13. [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia].
Hirayama Y; Sakamaki S; Takayanagi N; Tsuji Y; Sagawa T; Chiba H; Maeda M; Matsunaga T; Kato J; Niitsu Y
Rinsho Ketsueki; 2003 May; 44(5):334-8. PubMed ID: 12822409
[TBL] [Abstract][Full Text] [Related]
14. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
Rea D; Legros L; Raffoux E; Thomas X; Turlure P; Maury S; Dupriez B; Pigneux A; Choufi B; Reman O; Stéphane D; Royer B; Vigier M; Ojeda-Uribe M; Recher C; Dombret H; Huguet F; Rousselot P; ;
Leukemia; 2006 Mar; 20(3):400-3. PubMed ID: 16437142
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia.
Visani G; Piccaluga P; Malagola M; Isidori A
Leukemia; 2009 Sep; 23(9):1687-8. PubMed ID: 19421228
[No Abstract] [Full Text] [Related]
16. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
Singh T; Casson C
Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
[TBL] [Abstract][Full Text] [Related]
17. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
Fuster JL; Bermúdez M; Galera A; Llinares ME; Calle D; Ortuño FJ
Haematologica; 2007 Dec; 92(12):1723-4. PubMed ID: 18056006
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.
Koca E; Sevimli F; Cetiner D; Haznedaroglu IC; Sayinalp N; Büyükasik Y; Goker H; Ozcebe O
Am J Hematol; 2007 Apr; 82(4):333. PubMed ID: 17094091
[No Abstract] [Full Text] [Related]
20. [The role of imatinib in the treatment of acute lymphoid leukemias].
Poros A; Lovas N
Orv Hetil; 2005 May; 146(18 Suppl 1):905-10. PubMed ID: 15921303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
